Spark updates Luxturna prescribing information with FDA for complications observed post-marketing (Cell and Gene Therapy Catapult – Regulatory Round-up – Juin 2022)
The FDA has approved an update to the voretigene neparvovec-rzyl (Luxturna) post-marketing experience section of the label to include the occurrence chorioretinal atrophy.
See all of Catapult’s Regulatory Round-up for June 2022 here.
Published on the 1st of July 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (27 octobre 2022). Spark updates Luxturna prescribing information with FDA for complications observed post-marketing (Cell and Gene Therapy Catapult – Regulatory Round-up – Juin 2022). ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o643





